| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 07/20/2000 | CA2360584A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360346A1 Improved microbial preparations |
| 07/20/2000 | CA2360268A1 Pre-conditioning against cell death |
| 07/20/2000 | CA2360243A1 Use of lactobacillus salivarius |
| 07/20/2000 | CA2359990A1 Novel aralkyl amines of spirofuropyridines useful in therapy |
| 07/20/2000 | CA2359798A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith |
| 07/20/2000 | CA2359110A1 Combination of hepatitis b vaccine with antiviral agents |
| 07/20/2000 | CA2355374A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/19/2000 | EP1020529A2 Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| 07/19/2000 | EP1020474A1 Oligosaccharide derivatives and process for producing the same |
| 07/19/2000 | EP1020466A1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| 07/19/2000 | EP1020461A2 Use of alkaline salts of the (-)-enantiomer of omeprazole |
| 07/19/2000 | EP1020460A2 The sodium salt of the (-)-enantiomer of omeprazole |
| 07/19/2000 | EP1020193A1 Oral preparation |
| 07/19/2000 | EP1019488A1 Feed product |
| 07/19/2000 | EP1019412A1 Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht 1d? receptor antagonists |
| 07/19/2000 | EP1019410A1 Spiro-piperidine derivatives and their use as tachykinin antagonists |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019408A1 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- |
| 07/19/2000 | EP1019406A1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019394A1 PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| 07/19/2000 | EP1019386A1 Reverse hydroxamate derivatives as metalloprotease inhibitors |
| 07/19/2000 | EP1019066A1 Methods and compositions for preventing and treating heartburn |
| 07/19/2000 | EP1019046A1 Protease inhibitors |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP1019038A1 Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
| 07/19/2000 | EP1019036A1 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation |
| 07/19/2000 | EP0735877B1 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| 07/19/2000 | EP0661966B1 Ulcer prevention and treatment composition and method |
| 07/19/2000 | CN1260795A Quaternary ammonium compounds as tachykinin antagenists |
| 07/19/2000 | CN1260794A 5-aryl-3-(8-azabicyclo (3.2.2) oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as -5HT4 receptor ligands |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260778A Prostaglandin pharmaceutical compositions |
| 07/19/2000 | CN1260347A Chlorophyll alpha degraded product metal complex, its preparation method and medicament for anti-gastric ulcer |
| 07/19/2000 | CN1260206A Medicine for relieving stomach-ache and turgor |
| 07/19/2000 | CN1260205A Medicine for appendicitis |
| 07/19/2000 | CN1260199A Multifunction quick-effect health medicinal plaster |
| 07/19/2000 | CN1260198A External-applied Chinese herbal medicine plaster for treating hepatitis B preparation method |
| 07/19/2000 | CN1260186A Kouchuangjin (wiping out aphtha) and its preparation technology |
| 07/19/2000 | CN1054542C Medicine for treating liver diseases and preparation method thereof |
| 07/19/2000 | CN1054540C Anti-hepatitis B virus preparation of traditional Chinese medicine and its preparation method |
| 07/19/2000 | CN1054539C Chinese herbal powdered medicine for treating hepatitis B |
| 07/19/2000 | CN1054518C Preparatory Chinese medicine for treating choletihiasis, cholecystitis and biliary tract obstruction and preparing method thereof |
| 07/19/2000 | CN1054515C Chinese medicine for treating hepatitis B |
| 07/19/2000 | CN1054512C Physiological multi-salt solution |
| 07/19/2000 | CN1054511C Physiological multi-salt powder |
| 07/19/2000 | CN1054506C Pharmaceutical composition use |
| 07/19/2000 | CN1054504C Tooth-cleaning unit |
| 07/18/2000 | US6090945 Tetrahydro-beta-carbolines |
| 07/18/2000 | US6090944 Alkanoic acid derivatives as αv integrin receptor antagonists |
| 07/18/2000 | US6090852 Matrix metalloprotease inhibitor |
| 07/18/2000 | US6090840 Peptidyl compounds having MMP and TNF inhibitory activity |
| 07/18/2000 | US6090827 Pharmaceutical formulation of omeprazole |
| 07/18/2000 | US6090818 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them |
| 07/18/2000 | US6090612 Polynucleotide sequence coding a phosphatase enzymes; a diagnostic tool for monitoring enzyme activity in sample; for treatment of nervous system disorders, cardiovascular disorders and tumors; antitumor agents |
| 07/18/2000 | US6090611 Helicobacter pylori proteins useful for vaccines and diagnostics |
| 07/18/2000 | US6090579 Human SDR2 cDNA clone |
| 07/18/2000 | US6090544 Screening for compounds capable of activating osteogenic protein-1-responsive transcription activating element by transforming cell with dna of element linked to reporter gene, exposing cell to compound, determining gene expression |
| 07/18/2000 | US6090410 Dry mix formulation for bisphosphonic acids |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | CA2129051C Absorbable composite materials for use in the treatment of periodontal disease |
| 07/18/2000 | CA2006716C Antibacterial antiplaque oral composition |
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040613A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040600A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040576A2 Thiopyran compounds as inhibitors of mmp |
| 07/13/2000 | WO2000040570A1 Oxazepine derivatives and drugs containing the same |
| 07/13/2000 | WO2000040569A1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040560A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 07/13/2000 | WO2000040263A1 Production and use of a composition containing ivig for treating diseases that are characterized by elevated extracellular fasl titers |
| 07/13/2000 | WO2000040258A1 Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation |
| 07/13/2000 | WO2000040247A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | WO2000040239A1 Compounds and methods |
| 07/13/2000 | WO2000040228A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000024897B1 Cell surface molecule-induced macrophage activation |
| 07/13/2000 | WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000021986A3 Matrix-remodeling genes |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000010582A3 Probiotic, lactic acid-producing bacteria and uses thereof |
| 07/13/2000 | DE19900503A1 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen mit erhöhten extrazellulären FasL-Titern, Verfahren zur prophylaktischen Eignungs- bzw. Qualitätskontrolle derselben, Verfahren zur Herstellung von Arzneimitteln zur Behandlung obiger Krankheiten mit gesteigerter Wirksamkeit Use of a composition for the manufacture of a medicament for the treatment of diseases with increased extracellular FasL titers method for the prophylactic or suitability quality control thereof, a process for the preparation of medicaments for the treatment of the above diseases with enhanced efficacy |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |